Godalming, UK-based Sinclair Pharma has posted a pleasing set of results for the first six months of its financial year, with a double-digit rise in revenues helping to cut down loss for the period.
The company generated sales of £10.4 million for the six months to December 31, 2007, marking growth of 15% despite various challenges such as the delay to the US launch of its gum disease product Decapinol and flat sales of flagship eczema drug Atopiclair in the USA due to a contracted market during the period.
And this solid growth in sales allowed the group to cut its operating loss down to £900,000 from £2.6 million in year-ago period, with loss per share coming in at 1.1 pence compared to 3.1 pence, respectively.
Furthermore, Sinclair is confident that this success will continue through the second half of the year, with product line extensions, launches and new registrations during the first half expanding its portfolio of products and sales.
“We are committed to growing sales in line with expectations during the second half of the year, while keeping costs under control,” commented the firm’s chairman, Steve Harris, adding: “We have already seen a strong start to the second half, with a record order book.”
